Natco Pharma’s arm makes $8 million investment in eGenesis

04 Sep 2024 Evaluate

Natco Pharma’s wholly owned subsidiary -- NATCO Pharma (Canada) Inc., has made an investment of $8 million in eGenesis, Inc., a biotechnology company at the forefront of xenotransplantation focused on developing safe and effective human-compatible organs for transplant. In March 2024, eGenesis announced the world’s first porcine kidney transplant in a living patient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway.

With this, the company is investing in new-age therapeutic programmes addressing critical unmet medical needs.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. 


Natco Pharma Share Price

797.60 -38.80 (-4.64%)
04-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1709.40
Dr. Reddys Lab 1109.75
Cipla 1415.55
Lupin 1971.10
Zydus Lifesciences 866.65
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...